Merck highlights subcutaneous demand even as Keytruda sales soar
01 Feb 2024
Drug Approval
Merck said Keytruda sales jumped 21% to $6.6 billion in the fourth quarter of the year, driven by new approvals in earlier-stage indications for breast cancer and renal cell carcinoma, and more demand in metastatic cancers.
The company’s crown jewel made up nearly half of its revenue in the final three months of the year.
The blockbuster scored multiple approvals last year, including in combination with Astellas and Pfizer’s Padcev for first-line treatment of urothelial cancer; with chemoradiotherapy for a specific late-stage cervical cancer; as a first-line treatment for HER2-negative gastric cancer; and in combination with gemcitabine and cisplatin for biliary tract cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.